Oxipurinol
Appearance
(Redirected fromOxypurinol)
Names | |
---|---|
Preferred IUPAC name
1H-pyrazolo[3,4-d]pyrimidine-4,6(2H,5H)-dione | |
Other names
2,5-Dihydro-1H-pyrazolo[3,4-d]pyrimidine-4,6-dione
Alloxanthine | |
Identifiers | |
3D model (JSmol)
|
|
139956 | |
ChEBI | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.017.792 |
EC Number |
|
KEGG | |
MeSH | Oxypurinol |
PubChemCID
|
|
UNII | |
CompTox Dashboard(EPA)
|
|
| |
| |
Properties | |
C5H4N4O2 | |
Molar mass | 152.11086 |
Appearance | white crystals |
Except where otherwise noted, data are given for materials in theirstandard state(at 25 °C [77 °F], 100 kPa).
|
Oxipurinol(INN,oroxypurinolUSAN) is aninhibitorofxanthine oxidase.[1]It is anactive metaboliteofallopurinoland it is cleared renally.[2]In cases of renal disease, this metabolite will accumulate to toxic levels. By inhibiting xanthine oxidase, it reducesuric acidproduction. High serum uric acid levels may result ingout,kidney stones,and other medical conditions.
References
[edit]- ^Stocker, Sophie L; McLachlan, Andrew J; Savic, Radojka M; Kirkpatrick, Carl M; Graham, Garry G; Williams, Kenneth M; Day, Richard O (2012)."The pharmacokinetics of oxypurinol in people with gout".British Journal of Clinical Pharmacology.74(3): 477–489.doi:10.1111/j.1365-2125.2012.04207.x.PMC3477349.PMID22300439.
- ^Elion, Gertrude B; Yü, Ts'ai-Fan; Gutman, Alexander B; Hitchings, George H (1968). "Renal clearance of oxipurinol, the chief metabolite of allopurinol".The American Journal of Medicine.45(1): 69–77.doi:10.1016/0002-9343(68)90008-9.PMID5658870.